# Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma

> **NCT04911621** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Antwerp** · enrollment: 10 (estimated)

## Conditions studied

- High Grade Glioma
- Diffuse Intrinsic Pontine Glioma

## Interventions

- **BIOLOGICAL:** Dendritic cell vaccination + temozolomide-based chemoradiation
- **BIOLOGICAL:** Dendritic cell vaccination +- conventional next-line treatment

## Key facts

- **NCT ID:** NCT04911621
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-10
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911621, "Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04911621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*